Members of our team had the opportunity to present a new poster abstract at the 2023 NASP Annual Meeting & Expo, which was held from September 18-21, and at AMCP Nexus 2023 from October 16-19.
Background
- Linkage to care initiatives can accelerate education about therapeutic advancements and promote awareness of new medication indications.
- Health system specialty pharmacy (HSSP) pharmacists are embedded within clinics where they can offer linkage to care services by collaborating with prescribers and patients to ensure optimal therapy, identify high-risk patients, and provide education on changes to medication labeling.
- In October 2021, the U.S. Food and Drug Administration (FDA) approved abemaciclib as the first therapy to treat patients with hormone receptor positive (HR+), human epidermal growth facrot receptor 2 negative (HER2-), node-positive early breast cancer (EBC) who are at high risk of recurrence, as an adjunct to endocrine therapy (ET).
- Abemaciclib was identified as having morbidity and mortality benefit, therefore prompting a need for a linkage to care initiative to identify patients who otherwise would not have been identified in a timely manner.
Objectives
The objective of this study is to describe the linkage to care initiative performed by HSSP pharmacists in evaluating patients with EBC who may benefit from abemaciclib therapy based on new FDA indication approval.
Read about the team's findings by downloading the Outcomes Study below.
Download the abstract: